Characteristics of patients in the matched control study
Characteristic . | IFM 2005-01 (n = 115) . | IFM Bor-HDM (n = 46) . |
---|---|---|
Sex, M/F, n | 60/55 | 24/22 |
Median age, y (range) | 58 (32-65) | 58 (40-65) |
Isotype, % | ||
IgG | 69 | 67 |
IgA | 20 | 20 |
LC | 7 | 9 |
Others | 4 | 4 |
ISS stage, % | ||
I | 48 | 52 |
II | 36 | 22 |
III | 16 | 26 |
Median β2-microglobulin level, mg/L (range) | 3.3 (1.3-41.9) | 3.3 (1.7-15.7) |
Median albumin level, g/L (range) | 39 (22-54) | 39 (18-52) |
FISH analysis, n/evaluable patients (%) | ||
del(13q) | 59/113 (52) | 21/42 (50) |
del(17p) and/or t(4;14) | 14/113 (12) | 8/37 (21) |
Frontline treatments, n (%)* | ||
VAD | 70 (61) | 28 (61) |
Bor/Dex | 45 (39) | 18 (39) |
Response to induction therapy, n (%)* | ||
SD | 15 (13) | 6 (13) |
PR | 60 (52) | 24 (52) |
VGPR | 35 (30) | 14 (30) |
CR | 5 (5) | 2 (5) |
Characteristic . | IFM 2005-01 (n = 115) . | IFM Bor-HDM (n = 46) . |
---|---|---|
Sex, M/F, n | 60/55 | 24/22 |
Median age, y (range) | 58 (32-65) | 58 (40-65) |
Isotype, % | ||
IgG | 69 | 67 |
IgA | 20 | 20 |
LC | 7 | 9 |
Others | 4 | 4 |
ISS stage, % | ||
I | 48 | 52 |
II | 36 | 22 |
III | 16 | 26 |
Median β2-microglobulin level, mg/L (range) | 3.3 (1.3-41.9) | 3.3 (1.7-15.7) |
Median albumin level, g/L (range) | 39 (22-54) | 39 (18-52) |
FISH analysis, n/evaluable patients (%) | ||
del(13q) | 59/113 (52) | 21/42 (50) |
del(17p) and/or t(4;14) | 14/113 (12) | 8/37 (21) |
Frontline treatments, n (%)* | ||
VAD | 70 (61) | 28 (61) |
Bor/Dex | 45 (39) | 18 (39) |
Response to induction therapy, n (%)* | ||
SD | 15 (13) | 6 (13) |
PR | 60 (52) | 24 (52) |
VGPR | 35 (30) | 14 (30) |
CR | 5 (5) | 2 (5) |
Ig indicates immunoglobulin; LC, light chain; ISS, International Staging System; FISH, fluorescence in situ hybridization; VAD, vincristine, Adriamycin, and dexamethasone; Bor/Dex, bortezomib and dexamethasone; SD, stable disease; PR, partial response; VGPR, very good partial response; and CR, complete response.
Distributions are identical due to matching.